

Low molecular weight heparin · Lactoferrin, a glycoprotein derived from breastmilk, is recognized for its health benefits in infants and children; however, its protective effects when administered Keywords: Food and Drug Administration; drug safety; drugs; lactation; pregnancy; teratogens Pregnancy and Medication Use •Six million pregnancies in US every year •50% of pregnant women reported taking at least one medication • Pregnant women take an average of With the Food and Drug Administration (FDA) changing from the letter category system format for indicating fetal and infant risk to the new Pregnancy and Lactation Labeling Rule, the FDA is relying on practitioners to assess a more narrative description of Vol() Vol() Vol() Women frequently take a variety of drugs during pregnancy and lactation, including prescription, over the counter, and herbal agents. It is well known that pregnancy induces significant changes in both pharmacokinetics and pharmacodynamics of most drugs with a high intra and interpatient variabilityAn easy A-to-Z format lists more than 1, of the most commonly prescribed drugs taken during pregnancy and lactation, with detailed monographs designed to provide the most essential information on possible effects on the mother, embryo, fetus, and nursing infant It covers an exhaustive list of common and less common drugs and provides for each drug the FDA letter categorization and newly approved "Pregnancy and Lactation Labeling Rule (PLLR)" The chapter provides the foundations for the safest isions for the mother and her breastfed infant through a review of the physiology of lactation, the lactation pharmacology, and the specific pharmacology and infant safety of drugs common to everyday obstetric practice Existing animal models need to be improved to address the mechanisms of actions of drugs and drug toxicity in pregnancy, while assessing clinical outcomes. Effective animal models and newer research techniques to study the use of medications during lactation are lacking With the Food and Drug Administration (FDA) changing from the letter category system format for indicating fetal and infant risk to the new Pregnancy and Lactation Labeling These initial models are then applied to pregnancy by incorporating known drug properties and drug behavior changes in pregnancy such as the well-recognized increase in renal Tinzaparin does not cross the human placenta; increased risks of fetal bleeding or teratogenic effects have not been reported (Bates).